Potential Application of CAR-NK Cells as an Ex Vivo Therapy for T-cell-related Diseases
Frontiers in Bioscience-Landmark · 11.03.2026 · 31 (3)
DOI: 10.31083/fbl48704 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Frontiers in Bioscience-Landmark, online erschienen am 11.03.2026. Verfasst von Daekee Kwon und 1 weiteren Autor:innen. Beteiligte Einrichtung: Research Institute, Maru Therapeutics Co., Ltd., Seoul BioHub Global Center, Dongdaemun-gu, 02455 Seoul, Republic of Korea. Hauptthemen laut MEDLINE: T-Lymphocytes, Killer Cells, Natural, Receptors, Chimeric Antigen, Immunotherapy, Adoptive. Die Arbeit nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Korean Fund for Regenerative Medicine (KFRM) grant.
Abstract (Originalsprache)
Anticancer therapeutics have evolved from small-molecule drugs to monoclonal antibodies and, more recently, to cell and gene therapies (CGTs). This progress has been driven by the pursuit of greater drug specificity, potency, and safety. Recent breakthroughs in chimeric antigen receptor T-cell (CAR-T) therapy for B-cell hematologic malignancies have accelerated the development of CAR-X CGTs, including CAR-T, CAR-natural killer (CAR-NK), and CAR-macrophage approaches. In this article, we compare candidate CAR-X platforms for T-cell–related diseases, such as T-cell hematologic malignancies, and propose the most suitable modality. Therefore, we analyzed the advantages and limitations of CAR-T, CAR-NK, and CAR-macrophage therapies. In T-cell-related diseases, CAR-T therapy faces multiple challenges, including fratricide, T-cell aplasia, and substantial barriers to the generation of allogeneic CAR-T products. CAR-macrophage therapies, in contrast, are constrained by relatively limited efficacy. In contrast, CAR-NK cells do not cause fratricide or T-cell aplasia and can be manufactured efficiently as allogeneic, “off-the-shelf” products. Collectively, to sustain and extend the advances in CGT initiated by CAR-T cells in B-cell malignancies, prioritizing CAR-NK research infrastructure for T-cell–related diseases represents a rational and strategic approach.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Research Institute, Maru Therapeutics Co., Ltd., Seoul BioHub Global Center, Dongdaemun-gu, 02455 Seoul, Republic of Korea.
- Department of Veterinary Medicine, College of Veterinary Medicine, Seoul National University, 08826 Seoul, Republic of Korea.
- Adult Stem Cell Research Center, College of Veterinary Medicine, Seoul National University, 08826 Seoul, Republic of Korea.
Förderung
- Korean Fund for Regenerative Medicine (KFRM) grant
Zitieren
APA
Kwon, D., & Kang, K. S. (2026). Potential Application of CAR-NK Cells as an Ex Vivo Therapy for T-cell-related Diseases. Frontiers in Bioscience-Landmark, 31(3). https://doi.org/10.31083/fbl48704
Vancouver
Kwon D, Kang KS. Potential Application of CAR-NK Cells as an Ex Vivo Therapy for T-cell-related Diseases. Frontiers in Bioscience-Landmark. 2026;31(3). doi:10.31083/fbl48704
BibTeX
@article{Kwon2026,
author = {Kwon, Daekee and Kang, Kyung-Sun},
title = {Potential Application of CAR-NK Cells as an Ex Vivo Therapy for T-cell-related Diseases},
journal = {Frontiers in Bioscience-Landmark},
year = {2026},
volume = {31},
number = {3},
doi = {10.31083/fbl48704}
}
EUVIMED